Zolunicant (MM-110) is a potent nicotinic α3β4 receptor inhibitor with an IC50 of 0.90 μM, showing promise in combating addiction. It effectively reduces self-administration of addictive agents such as morphine, cocaine, methamphetamine, nicotine, and ethanol in rat models, indicating its potential as a treatment for various forms of drug abuse [1]. Additionally, Zolunicant exhibits strong leishmanicidal activity against Leishmania amazonensis, expanding its therapeutic prospects [2].

Zolunicant (18-MC; 0.01-100 μM) shows an inhibitory activity against nicotinic α3β4 receptors with an IC 50 of 0.90 μM [1].. Zolunicant (18-MCOR; 0-20 μg/ml; 24h) also shows antiamastigote activity against L. amazonensis-infected macrophage [2]. Cell Viability Assay [2] Cell Line: L. amazonensis-infected macrophage Concentration: 0, 1, 10,15 and 20 μg/ml Incubation Time: 24 h Result: Decreased the amastigote survival by 73, 84, and 92%, respectively in the treatment with 18-MCOR at 1, 10, or 20 μg/ml.

Zolunicant (18-MC; Intravenous administration; 0-20 μg a day;14 days) decreases morphine self-administration by blocking α3β4 nicotinic receptors in the habenulo-interpeduncular pathway [3]. Animal Model: Na ve female Long-Evans derived rats [3] Dosage: 0,10 and 20 μg Administration: Intravenous administration; once a day; 14 days Result: Infused into the medial habenula and interpeduncular nucleus decreased morphine self-administration (interpeduncular nucleus: F(5,29) = 6.89, P < 0.0001; medial habenula: F(4,28) = 3.07, P < 0.03).